Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 697.0
(0.14%)
KRW 697.0
(0.14%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 32 Billion KRW | 24695.05% |
| 2022 | 129.05 Million KRW | 7.55% |
| 2021 | 120 Million KRW | -26.79% |
| 2020 | 163.91 Million KRW | -28.11% |
| 2019 | 228.01 Million KRW | 0.0% |
| 2018 | - KRW | -100.0% |
| 2017 | 24.89 Billion KRW | 2204.98% |
| 2016 | 1.08 Billion KRW | -73.91% |
| 2015 | 4.13 Billion KRW | -50.7% |
| 2014 | 8.39 Billion KRW | 0.76% |
| 2013 | 8.33 Billion KRW | 263.2% |
| 2012 | 2.29 Billion KRW | -43.12% |
| 2011 | 4.03 Billion KRW | -24.9% |
| 2010 | 5.37 Billion KRW | 0.0% |
| 2009 | - KRW | -100.0% |
| 2008 | 778.03 Million KRW | 0.0% |
| 2007 | - KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 32 Billion KRW | 0.0% |
| 2024 Q1 | 32 Billion KRW | 0.0% |
| 2023 Q3 | 38.53 Billion KRW | 2.02% |
| 2023 Q2 | 37.77 Billion KRW | 0.0% |
| 2023 FY | 32 Billion KRW | 24695.05% |
| 2023 Q1 | - KRW | -100.0% |
| 2023 Q4 | 32 Billion KRW | -16.97% |
| 2022 Q1 | 92.9 Million KRW | -22.58% |
| 2022 FY | 129.05 Million KRW | 7.55% |
| 2022 Q4 | 129.05 Million KRW | 349.99% |
| 2022 Q3 | 28.68 Million KRW | -47.09% |
| 2022 Q2 | 54.2 Million KRW | -41.65% |
| 2021 FY | 120 Million KRW | -26.79% |
| 2021 Q4 | 120 Million KRW | -17.02% |
| 2021 Q1 | 164.5 Million KRW | 0.36% |
| 2021 Q2 | 156.12 Million KRW | -5.1% |
| 2021 Q3 | 144.6 Million KRW | -7.37% |
| 2020 FY | 163.91 Million KRW | -28.11% |
| 2020 Q4 | 163.91 Million KRW | 0.0% |
| 2020 Q3 | - KRW | -100.0% |
| 2020 Q1 | 288.91 Million KRW | 26.71% |
| 2020 Q2 | 252.52 Million KRW | -12.6% |
| 2019 Q2 | 57.58 Million KRW | -72.49% |
| 2019 Q4 | 228.01 Million KRW | 41.02% |
| 2019 FY | 228.01 Million KRW | 0.0% |
| 2019 Q1 | 209.36 Million KRW | 0.0% |
| 2019 Q3 | 161.69 Million KRW | 180.78% |
| 2018 Q2 | - KRW | -100.0% |
| 2018 Q3 | - KRW | 0.0% |
| 2018 FY | - KRW | -100.0% |
| 2018 Q4 | - KRW | 0.0% |
| 2018 Q1 | 25.48 Billion KRW | 2.38% |
| 2017 Q4 | 24.89 Billion KRW | -1.91% |
| 2017 FY | 24.89 Billion KRW | 2204.98% |
| 2017 Q3 | 25.37 Billion KRW | 0.0% |
| 2017 Q2 | - KRW | -100.0% |
| 2017 Q1 | 945 Million KRW | -12.5% |
| 2016 FY | 1.08 Billion KRW | -73.91% |
| 2016 Q2 | 29.96 Billion KRW | 78.0% |
| 2016 Q3 | 15.72 Billion KRW | -47.53% |
| 2016 Q4 | 1.08 Billion KRW | -93.13% |
| 2016 Q1 | 16.83 Billion KRW | 306.73% |
| 2015 Q3 | 4.3 Billion KRW | -3.67% |
| 2015 Q4 | 4.13 Billion KRW | -3.81% |
| 2015 Q1 | 8.09 Billion KRW | -3.62% |
| 2015 Q2 | 4.46 Billion KRW | -44.79% |
| 2015 FY | 4.13 Billion KRW | -50.7% |
| 2014 Q2 | 8.69 Billion KRW | -1.43% |
| 2014 Q1 | 8.82 Billion KRW | 5.89% |
| 2014 FY | 8.39 Billion KRW | 0.76% |
| 2014 Q4 | 8.39 Billion KRW | -2.08% |
| 2014 Q3 | 8.57 Billion KRW | -1.42% |
| 2013 Q4 | 8.33 Billion KRW | 17.14% |
| 2013 FY | 8.33 Billion KRW | 263.2% |
| 2013 Q3 | 7.11 Billion KRW | 33.4% |
| 2013 Q2 | 5.33 Billion KRW | 17.38% |
| 2013 Q1 | 4.54 Billion KRW | 98.02% |
| 2012 FY | 2.29 Billion KRW | -43.12% |
| 2012 Q4 | 2.29 Billion KRW | 0.0% |
| 2012 Q1 | 3.58 Billion KRW | 0.0% |
| 2011 Q1 | 5.07 Billion KRW | 0.0% |
| 2011 FY | 4.03 Billion KRW | -24.9% |
| 2011 Q3 | 19.33 Billion KRW | 305.26% |
| 2011 Q2 | 4.77 Billion KRW | -5.92% |
| 2010 Q1 | - KRW | 0.0% |
| 2010 FY | 5.37 Billion KRW | 0.0% |
| 2010 Q2 | - KRW | 0.0% |
| 2009 Q4 | - KRW | 0.0% |
| 2009 FY | - KRW | -100.0% |
| 2009 Q2 | 830.1 Million KRW | 3.02% |
| 2009 Q1 | 805.79 Million KRW | 0.31% |
| 2008 FY | 778.03 Million KRW | 0.0% |
| 2008 Q2 | - KRW | 0.0% |
| 2008 Q1 | - KRW | 0.0% |
| 2008 Q4 | 803.29 Million KRW | 0.0% |
| 2007 Q1 | 6.73 Billion KRW | 0.0% |
| 2007 Q2 | 6.75 Billion KRW | 0.17% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | - KRW | 0.0% |
| 2007 Q3 | - KRW | -100.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -98.417% |
| Yuhan Corporation | 60.23 Billion KRW | 46.874% |
| Yuhan Corporation | 60.23 Billion KRW | 46.874% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -134.603% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -134.603% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -134.603% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | -7.107% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 35.443% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 84.163% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -6.667% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -6.667% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -6.667% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -31328.692% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 55.625% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -72.764% |
| HANDOK Inc. | 123.78 Billion KRW | 74.148% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -204.762% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -6626.324% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 59.249% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -26638.325% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 7.447% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 20.749% |
| Boryung Corporation | 151.7 Billion KRW | 78.907% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -5411.102% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -668.005% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -428.926% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -428.926% |
| Suheung Co., Ltd. | 74 Billion KRW | 56.761% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | -68.176% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -5320.888% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -10321.544% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -154.287% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -14514.475% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -14514.475% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -191.904% |
| CKD Bio Corp. | 69.43 Billion KRW | 53.911% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 65.744% |
| JW Holdings Corporation | 20.65 Billion KRW | -54.909% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 73.554% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 60.989% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 80.246% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | -6.667% |
| JW Lifescience Corporation | 168 Million KRW | -18947.619% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -115.849% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -618.777% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -1901.444% |